NASDAQ:WHWK Whitehawk Therapeutics (WHWK) Stock Price, News & Analysis $4.60 -0.03 (-0.65%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Whitehawk Therapeutics Stock (NASDAQ:WHWK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Whitehawk Therapeutics alerts:Sign Up Key Stats Today's Range$4.53▼$4.6550-Day Range$3.66▼$5.0852-Week Range$1.76▼$5.49Volume178,141 shsAverage Volume318,555 shsMarket Capitalization$262.25 millionP/E RatioN/ADividend YieldN/APrice Target$8.20Consensus RatingModerate Buy Company Overview Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. Read More Whitehawk Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreWHWK MarketRank™: Whitehawk Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 548th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingWhitehawk Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialWhitehawk Therapeutics has a consensus price target of $8.20, representing about 78.3% upside from its current price of $4.60.Amount of Analyst CoverageWhitehawk Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Whitehawk Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Whitehawk Therapeutics are expected to grow in the coming year, from ($1.10) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Whitehawk Therapeutics is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Whitehawk Therapeutics is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWhitehawk Therapeutics has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.62% of the float of Whitehawk Therapeutics has been sold short.Short Interest Ratio / Days to CoverWhitehawk Therapeutics has a short interest ratio ("days to cover") of 10.42, which indicates bearish sentiment.Change versus previous monthShort interest in Whitehawk Therapeutics has recently increased by 13.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWhitehawk Therapeutics does not currently pay a dividend.Dividend GrowthWhitehawk Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.13 News SentimentWhitehawk Therapeutics has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Whitehawk Therapeutics this week, compared to 2 articles on an average week. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Whitehawk Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders49.90% of the stock of Whitehawk Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.08% of the stock of Whitehawk Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Whitehawk Therapeutics' insider trading history. Receive WHWK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Whitehawk Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WHWK Stock News HeadlinesWhitehawk Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2026 | prnewswire.comWhitehawk Therapeutics Inc WHWKAugust 14, 2026 | morningstar.comMThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)August 10, 2026 | theglobeandmail.comWhitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial CancersAugust 6, 2026 | tipranks.comWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsAugust 6, 2026 | prnewswire.comBiocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC DevelopmentJuly 7, 2026 | businesswire.com10 Hot Biotech Stocks Under $5 to BuyJune 10, 2026 | insidermonkey.comSee More Headlines WHWK Stock Analysis - Frequently Asked Questions How have WHWK shares performed this year? Whitehawk Therapeutics' stock was trading at $2.42 at the beginning of the year. Since then, WHWK shares have increased by 90.1% and is now trading at $4.60. How were Whitehawk Therapeutics' earnings last quarter? Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) announced its earnings results on Thursday, August, 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.10. Who are Whitehawk Therapeutics' major shareholders? Top institutional investors of Whitehawk Therapeutics include Montanova Capital LLC (7.54%), BlackRock Inc. (3.89%), ADAR1 Capital Management LLC (2.35%) and Bank of New York Mellon Corp (0.17%). Insiders that own company stock include David James Lennon, Bryan Ball and Scott M Giacobello. View institutional ownership trends. How do I buy shares of Whitehawk Therapeutics? Shares of WHWK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2026Today9/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 WHWK's financial health is in the Green zone, according to TradeSmith. WHWK has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:WHWK CIK1422142 Webaadibio.com Phone(424) 473-8055FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Price Target for Whitehawk Therapeutics$8.20 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+78.3%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.60 million Net MarginsN/A Pretax Margin-288.26% Return on Equity-53.89% Return on Assets-49.97% Debt Debt-to-Equity RatioN/A Current Ratio17.38 Quick Ratio17.38 Sales & Book Value Annual Sales$7.14 million Price / Sales36.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.21 per share Price / Book1.43Miscellaneous Outstanding Shares57,010,000Free Float28,562,000Market Cap$262.25 million OptionableN/A Beta0.81 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:WHWK) was last updated on 9/6/2026 by MarketBeat.com Staff. From Our PartnersThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe trapdoor has a date on itRepublicans hold the House 220 to 215. Just three seats could flip control, and more than 35 GOP members have ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Whitehawk Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Whitehawk Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
